News Focus
News Focus
icon url

peregr

02/01/18 11:51 AM

#323680 RE: biopharm #323676

The fiduciary responsibility is to drive the most value for shareholders. Because of all the mistakes of the past, R&D or a CDMO became the binary choice. Eventually, the R&D would have bankrupt this Company. For those who still hope in the IP, put it in good hands where we can still have some chance of additional value.

Nobody is silencing anyone.

If Steve King and Carlton in some wild scenario end up with the IP, would you invest again with them?
icon url

revenue_monster

02/01/18 12:00 PM

#323681 RE: biopharm #323676

i don’t think 19 patients were dosed. not sure your stats are accurate. irrelevant anyway today.

We still have not heard about the 19 patients of 22 for Yervoy + Bavituximab